



**Correction to: Impact of new generation
hormone-therapy on cognitive function in elderly
patients treated for a metastatic prostate cancer:
Cog-Pro trial protocol**

Marie Lange, Heidi Laviec, Hélène Castel, Natacha Heutte, Alexandra Leconte, Isabelle Léger, Bénédicte Giffard, Aurélie Capel, Martine Dubois, Bénédicte Clarisse, et al.

► To cite this version:

Marie Lange, Heidi Laviec, Hélène Castel, Natacha Heutte, Alexandra Leconte, et al.. Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer, 2018, 18 (1), pp.110. 10.1186/s12885-017-3764-9 . inserm-02127779

HAL Id: inserm-02127779

<https://inserm.hal.science/inserm-02127779>

Submitted on 13 May 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CORRECTION

Open Access



Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Marie Lange^{1,2,3}, Heidi Laviec⁴, Hélène Castel^{3,5}, Natacha Heutte^{1,2}, Alexandra Leconte², Isabelle Léger^{1,3,6,7}, Bénédicte Giffard^{3,8}, Aurélie Capel², Martine Dubois^{3,5}, Bénédicte Clarisse², Elodie Coquan^{2,4}, Frédéric Di Fiore^{9,10}, Sophie Gouérand^{9,10}, Philippe Bartélémy¹¹, Laure Pierard¹¹, Karim Fizazi¹² and Florence Joly^{1,2,3,13*}

Correction

After publication of the original article [1] the authors found that Table 2 had been formatted incorrectly, meaning that some rows in the Table did not display the correct information.

An updated version of Table 2 is included with this Correction.

The original article has also been updated.

Author details

¹INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076 Caen, France.

²Clinical Research Department, Centre François Baclesse, 14076 Caen, France.

³Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076 Caen, France.

⁴Medical Oncology Department, Centre François Baclesse, 14076 Caen, France.

⁵Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen, France.

⁶UPO, Gustave Roussy, 94800 Villejuif, France. ⁷NeuroHIV Rehabilitation Unit, Bicêtre University Hospital, 94275 Le Kremlin Bicêtre, France.

⁸Normandie University, UNICAEN, EPHE Paris, INSERM, U1077, 14000 Caen, France.

⁹Medical Oncology Department, Centre Henri-Becquerel, 76000 Rouen, France.

¹⁰Digestive and Urology Oncology Unit, Rouen University Hospital, 76000 Rouen, France.

¹¹Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

¹²Medical Oncology Department, Gustave Roussy, 94800 Villejuif, France.

¹³Medical Oncology Department, CHU de Caen, 14000 Caen, France.

Received: 9 November 2017 Accepted: 9 November 2017

Published online: 30 January 2018

Reference

1. Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérand S, Bartélémy P, Pierard L, Karim F, Joly F. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. *BMC Cancer*. 2017;17:549. <https://doi.org/10.1186/s12885-017-3534-8>.

* Correspondence: fjoly@baclesse.unicancer.fr

¹INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076 Caen, France

²Clinical Research Department, Centre François Baclesse, 14076 Caen, France



Table 2 Used cognitive tests, questionnaires and biological tests

Evaluations	Before inclusion	At inclusion (baseline) ^b	3 months	6 months	12 months
Signed Informed Consent	✓				
Previous medical history	✓				
Cognitive assessment^a MoCA Grober-Buschke test Digit span forward and backward (WAIS-III) Code (WAIS III) Trail Making test Doors test Stroop Victoria Verbal fluencies Rey-Osterrieth Complex Figure Number location (VOSP) Years of education and fNART		✓ ✓ Only at inclusion	✓	✓	✓
Quality of life FACT-G, FACIT-F, FACT-Cog, HADS, ISI		✓	✓	✓	✓
Pain (VAS)	✓ ^c	✓	✓	✓	✓
ONLY for PATIENTS (group of interest and control group)					
Geriatric assessment^d G8 Charlson ADL IADL MNA Time up and go		✓	✓	✓	✓
Quality of life FACT-P		✓	✓	✓	✓
Adherence evaluation^e Morisky questionnaire Patient diary			✓	✓	✓
Biological tests^f		✓	✓	✓	✓
Specific blood samples for further research^g		✓			

MoCA Montreal Cognitive Assessment, WAIS Wechsler Adult Intelligence Scale, VOSP Visual Object and Space Perception Battery, fNART French National Adult Reading Test, ISI Insomnia Severity Index, VAS Visual Analog Scale, ADL Activities of Daily Living, IADL Instrumental Activities of Daily Living, MNA Mini-Nutritional Assessment

^aCognitive assessment will be performed by neuropsychologists

^bFor group of interest patients: before the start of the treatment or within 15 days after the start of treatment by abiraterone acetate or enzalutamide

^cHad to be ≤3 on the 0–10 pain VAS scale to meet with inclusion pain criteria

^dGeriatric assessment will be performed by a study nurse specialized in geriatric

^eAdherence evaluation will be performed only in group of interest patients

^fAt each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 h AM, fasting)

^g1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)